

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

No equality issues have been identified during the scoping process.

- | |
|---------------------------------------------------------------------------------------------------------------------|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---------------------------------------------------------------------------------------------------------------------|

The committee can only appraise the technology within its marketing authorisation and based on the evidence available. The committee will consider whether its recommendation has any impact on potential equality issues or health inequalities, The committee should be mindful of the extent to which their recommendations could disadvantage a particular group.

- | |
|------------------------------------------------------------------------------------------|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|------------------------------------------------------------------------------------------|

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

Approved by Associate Director (name): Ian Watson

Date: 16 December 2025